Vyluma Launches With Myopia Treatment In Phase 3 Development

Vyluma announced its establishment as a wholly-owned subsidiary of Nevakar Inc., focusing on pharmaceutical ophthalmic solutions. The pipeline of novel therapies is led by NVK002, a pharmaceutical atropine eye drop to slow the progression of myopia in children. NVK002 is currently in late phase 3 CHAMP clinical trial in the United States and Europe, and phase 2 in Asia. If NVK002 stays on its current timeline, it would potentially be the first approved treatment for myopia using atropine eye drops to slow the progression of pediatric myopia in the world.

“With the establishment of Vyluma, we are committing more research, education, and resources to the ophthalmic clinicians, and their patients, to ensure we are not only bringing future treatments to market but inviting an open dialogue on how to best partner together,” Navneet Puri, PhD, Founder, Chairman, and CEO, said in a company news release. “NVK002 to treat myopia is where Vyluma will make a significant impact as, potentially, the first company to offer this treatment option, if approved by the FDA.”

Vyluma has a total of five pharmaceutical assets in its pipeline to address unmet treatment needs in the eyecare market. In addition to NVK002 for myopia, programs include presbyopia, NVK029, night vision disturbance, NVK031, acute ocular pain, NVK032, and potentially the first treatment for hyperopia, NVK033.

“Today marks a huge step in our efforts to partner with the ophthalmic community and do more for clinicians to treat their patients,” said Houman Hemmati, MD, PhD, Chief Medical Officer of Vyluma. “We have an incredible opportunity to improve patient care and quality of life with our thoughtfully developed pipeline of products to address disease states with the greatest unmet need for patients around the globe.”

Vyluma has partnered with Zhaoke Ophthalmology, in China and southeast Asia, and Laboratories Théa, in Europe, for the commercialization of NVK002.